Table 1.
Main clinical and biological characteristics of the population
| General population (n = 51) | Subgroups of general population |
||||
|---|---|---|---|---|---|
| LBP population (n = 27) | Inflammatory LBP population (n = 10) | patients with sacroiliitis (CT and/or MRI) (n = 12) | patients ASAS+ (n = 6) | ||
| Demographical data | |||||
| Age, years | 38.12 (12.6) | 40.48 (11.2) | 41.5 (12.01) | 39.17 (10.78) | 38.5 (11.95) |
| Female | 28 (54.9) | 15 (55.56) | 7 (70) | 8 (66.67) | 5 (83.33) |
| Smoking | 22 (43.1) | 11 (40.74) | 5 (50) | 5 (41.67) | 3 (50) |
| Peripheric arthralgia | 39 (76.5) | 27 (100) | 10 (100) | 10 (83.33) | 6 (100) |
| Psoriasis | 7 (13.7) | 5 (18.52) | 2 (20) | 1 (8.33) | 0 (0) |
| Family history of psoriasis | 7 (13.7) | 5 (18.52) | 2 (20) | 0 (0) | 0 (0) |
| Family history of SpA | 3 (5.9) | 3 (11.11) | 3 (30) | 0 (0) | 0 (0) |
| Uveitis | 2 (3.9) | 0 (0) | 0 (0) | 1 (8.33) | 0 (0) |
| Data on digestive disease | |||||
| CD | 41 (80.4) | 23 (85.19) | 9 (90) | 11 (91.67) | 6 (100) |
| Anal involvement | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Disease duration for CT, years | 7.67 (7.95) | 7.07 (7.42) | 7.9 (10.4) | 12.17 (9.27) | 9.33 (6.89) |
| Disease duration for MRI, years | 7.18 (7.78) | 6.78 (7.24) | 7.5 (10.18) | 11.5 (9.08) | 8.83 (6.34) |
| CD Montreal classification | |||||
| L1 | 11 (26.8) | 7 (25.9) | 4 (40) | 3 (25.17) | 1 (16.67) |
| L2 | 3 (7.3) | 2 (7.41) | 1 (10) | 0 (0) | 0 (0) |
| L3 | 27 (65.9) | 14 (51.85) | 3 (30) | 7 (58.3) | 4 (66.67) |
| UC Montreal classification | |||||
| E1 | 1 (10) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| E2 | 1 (10) | 0 (0) | 0 (0) | 1 (8.33) | 1 (16.67) |
| E3 | 8 (80) | 4 (14.8) | 2 (20) | 1 (8.33) | 0 (0) |
| Surgery | 25 (49) | 14 (51.85) | 5 (50) | 8 (66.67) | 4 (66.67) |
| Biological inflammation (CRP >5) at the time of MRI | 46 (90.2) | 25 (92.59) | 9 (90) | 9 (75) | 5 (83.33) |
| Bowel flare-up on endoscopy (n = 30) | 24 (80) | 11 (40.74) | 4 (40) | 4 (33.33) | 2 (33.33) |
| Bowel flare-up on MRI | 33 (64.7) | 18 (66.67) | 6 (60) | 9 (75) | 5 (83.33) |
| Global flare-up | 35 (68.6) | 16 (59.26) | 8 (80) | 7 (58.33) | 2 (33.33) |
| Therapy at the time of CT | |||||
| Corticotherapy | 8 (15.7) | 5 (18.52) | 1 (10) | 0 (0) | 0 (0) |
| Immunosuppressor | 10 (5.1) | 6 (22.22) | 3 (30) | 1 (8.33) | 0 (0) |
| Biological | 8 (15.7) | 3 (11.11) | 2 (20) | 3 (25) | 0 (0) |
| Therapy at the time of MRI | |||||
| Corticotherapy | 14 (27.5) | 8 (29.63) | 3 (30) | 3 (25) | 2 (33.33) |
| Immunosuppressor | 18 (35.3) | 10 (37.04) | 3 (30) | 3 (25) | 2 (33.33) |
| Biological | 23 (45.1) | 9 (33.33) | 1 (10) | 7 (58.33) | 2 (33.33) |
ASAS, Assessment of Spondylo Arthritis International Society; CD, Crohn's disease; CRP, C-reactive protein; CT, computed tomography; LBP, low back pain; MRI, magnetic resonance imaging; SpA, spondyloarthritis; UC, ulcerative colitis.